click below
click below
Normal Size Small Size show me how
Chapter 16
Blood-Modifying, Antineoplastic, and Immunosuppressant Drugs
| Question | Answer |
|---|---|
| Cell cycle–nonspecific | Capable of acting in several or all cell cycle phases. |
| Cell cycle–specific | Capable of acting during a particular cell cycle phase only. |
| Cytotoxic | Capable of destroying cells. |
| Disseminated intravascular coagulation (DIC) | Widespread formation of clots (thrombi) in the microscopic blood vessels of the circulatory system. DIC occurs as a complication of a wide variety of disorders and consumes clotting factors, with resultant bleeding. |
| Endothelial layer | The smooth layer of epithelial cells that line blood vessels. |
| Erythropoietin | A glycoprotein hormone secreted mainly by the kidney; it acts on stem cells of the bone marrow to stimulate red blood cell production. |
| Fibrinolysis | Fibrin (clot) breakdown through the action of the enzyme plasmin. |
| Hybridoma | A cell culture that consists of a clone of a hybrid cell formed by fusing cells of different types, such as stimulated mouse plasma cells and myeloma cells |
| Metastasis | Generally, refers to the transfer of cancer cells from one site to another. |
| Myeloma | A malignant neoplasm of plasma cells (B lymphocytes). |
| Myelosuppression | Inhibition of bone marrow activity that results in decreased production of blood cells and platelets. |
| Thrombocytopenia | A decreased number of platelets. |
| Thromboembolism | The condition that occurs when thrombus material becomes dislodged and is transported by the bloodstream to another site. |
| Thrombus | A clot in the circulatory system. |
| Vesicant | A substance that causes blister formation. |